Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 1:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1945–1968 of 8,271 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Age Clear all

Conditions: Macular Degeneration
Interventions: Lutein; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hematoma
Interventions: CEUS or Contrast enhanced Ultrasound; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Diabetic Peripheral Neuropathy
Interventions: Skin biopsy, Lidocaine 5% patches; Procedure · Drug
Lead sponsor: Albany Medical College; Other
Eligibility: 18 Years to 70 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Albany, New York

Conditions: Vestibular, Performance
Interventions: VOR and coordination measurements; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Fever
Interventions: Acetaminophen Arm, Placebo Arm, Ibuprofen Arm; Other
Lead sponsor: Duke University; Other
Eligibility: 6 Months to 47 Months
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Type 1 Diabetes Mellitus
Interventions: Developmental & Technological Demands, Distress Reduction, Nutrition, Set Point, & C:I Ratio, Hypoglycemia management, Minimal Intervention; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 2 Years to 6 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Autism Spectrum Disorder
Interventions: hCT-MSC infusion; Biological
Lead sponsor: Duke University; Other
Eligibility: 18 Months to 48 Months
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy
Interventions: HCV-796; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: Gainesville, Florida • Philadelphia, Pennsylvania

Conditions: Colorectal Cancer, Inflammatory Bowel Diseases, Diverticular Diseases, Social Behavior
Interventions: no intervention; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Alexander City, Alabama • Demopolis, Alabama • Greenville, Alabama

Conditions: Congenital Adrenal Hyperplasia
Interventions: Chronocort, Cortef, Placebo; Drug · Other
Lead sponsor: Neurocrine UK Limited; Industry
Eligibility: 16 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 11
States / cities: Los Angeles, California • Orange, California • Jacksonville, Florida + 8 more

Conditions: Pneumococcal Disease
Interventions: V116, PPSV23; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 2,162 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 30
States / cities: Mesa, Arizona • Tempe, Arizona • Little Rock, Arkansas + 27 more

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: SPD489; Drug
Lead sponsor: Shire; Industry
Eligibility: 4 Years to 5 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 50
States / cities: Dothan, Alabama • Little Rock, Arkansas • Imperial, California + 41 more

Conditions: Pancreatic Pseudocyst(s)
Interventions: AXIOS Stent & Delivery System; Device
Lead sponsor: Xlumena, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 6
States / cities: San Francisco, California • Aurora, Colorado • Jacksonville, Florida + 3 more

Conditions: Patent Ductus Arteriosus (PDA)
Interventions: PDA Coil; Device
Lead sponsor: PFM Medical, Inc; Industry
Eligibility: 6 Months to 21 Years
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 11
States / cities: Loma Linda, California • Los Angeles, California • Madera, California + 8 more

Conditions: Convulsion, Non-Epileptic
Interventions: ReACT; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 11 Years to 18 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Macular Degeneration
Interventions: Angiography, Laser Treatment; Procedure
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 50 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Nutritional Stunting, Growth Failure
Interventions: Essential Amino Acid (EAA) group, Placebo; Dietary Supplement
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 3 Years to 11 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Viral Upper Respiratory Tract Infection
Interventions: ARMS-I; Drug
Lead sponsor: University of Toledo Health Science Campus; Other
Eligibility: 18 Years to 45 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: Eosinophilic Esophagitis
Interventions: Eosinophilic Esophagitis (EoE) food introduction-1st, Eosinophilic Esophagitis (E0E) food introduction-2nd, Eosinophilic Esophagitis (EoE) Food introduction-3rd dose, Dupilumab; Dietary Supplement · Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 6 Years to 25 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Cancer (Adenocarcinoma), Prostate Specific Antigen
Interventions: Positron Emission Tomography (PET); Diagnostic Test
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Upper Gastrointestinal Motility Disorders
Interventions: Not listed
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 10 Years to 18 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Contraception
Interventions: TV-46046, Depo-subQ Provera; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Cypress, California • San Antonio, Texas

Conditions: Varicella Zoster Virus Infection
Interventions: Shingrix; Drug
Lead sponsor: University of Washington; Other
Eligibility: 30 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Turner Syndrome
Interventions: Not listed
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: Up to 3 Months · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Lutein for Age-Related Macular Degeneration

Utility of Real-Time Contrast Enhanced Ultrasound (CEUS) in the Evaluation of Soft Tissue Hematomas

Use of Topical Lidocaine to Reduce Pain in Patients With Diabetic Neuropathy

VOR Suppression in Non-Gymnast Adults

The Effect of Prophylactic Antipyretics on Immune Responses and Fever After 2014-2015 and 2015-2016 Inactivated Influenza Vaccine

Supporting Parents of Young Children With Type 1 Diabetes in Closed-Loop System

Open Label Phase I hCT-MSC in Toddlers With Autism Spectrum Disorder

Study to Evaluate the Effects of Age & Gender on PK, Safety & Tolerability of HCV-796 Administered to Healthy Subjects

The Deep South Surgical Equity Research Network: Addressing Socioecological Determinants of Health

Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia

A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)

Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder

AXIOS Stent & Delivery System Study

Nit-Occlud PDA Post-Approval Study

Retraining and Control Therapy (ReACT): Sense of Control and Symptom Expectations as Targets of a Treatment for PNES

Identification and Treatment of Feeder Vessels in Macular Degeneration

Nutritional Stimulation of Growth in Children With Short Stature

ARMS-I (a Formulation of Cetylpyridinium Chloride -CPC)

Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis

Flotufolastat F 18 PET in Men With Very Low PSA Recurrence

Use of an Ambulatory Capsule to Characterize Gastrointestinal Pressure Patterns in Children

A Study to Evaluate the Pharmacokinetics (PK) of Medroxyprogesterone Acetate Following an Injection of TV-46046 in Healthy Women of Reproductive Age

VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination

Turner Syndrome Prenatal Diagnosis Study